BioInvent International AB (publ)

OM:BINV Stock Report

Market Cap: SEK 2.7b

BioInvent International Management

Management criteria checks 3/4

BioInvent International's CEO is Martin Welschof, appointed in Sep 2018, has a tenure of 6.33 years. total yearly compensation is SEK5.17M, comprised of 55.5% salary and 44.5% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth SEK929.59K. The average tenure of the management team and the board of directors is 3.9 years and 5.8 years respectively.

Key information

Martin Welschof

Chief executive officer

SEK 5.2m

Total compensation

CEO salary percentage55.5%
CEO tenure6.3yrs
CEO ownership0.03%
Management average tenure3.9yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?

Aug 16
Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?

We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

Apr 09
We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Sep 01
Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive

Jun 02
Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive

Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week

Feb 25
Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week

We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Sep 28
We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook

Aug 31
Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook

CEO Compensation Analysis

How has Martin Welschof's remuneration changed compared to BioInvent International's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 410m

Jun 30 2024n/an/a

-SEK 383m

Mar 31 2024n/an/a

-SEK 335m

Dec 31 2023SEK 5mSEK 3m

-SEK 330m

Sep 30 2023n/an/a

-SEK 311m

Jun 30 2023n/an/a

-SEK 304m

Mar 31 2023n/an/a

-SEK 48m

Dec 31 2022SEK 5mSEK 3m

-SEK 43m

Sep 30 2022n/an/a

-SEK 43m

Jun 30 2022n/an/a

-SEK 42m

Mar 31 2022n/an/a

-SEK 266m

Dec 31 2021SEK 5mSEK 3m

-SEK 278m

Sep 30 2021n/an/a

-SEK 171m

Jun 30 2021n/an/a

-SEK 141m

Mar 31 2021n/an/a

-SEK 123m

Dec 31 2020SEK 5mSEK 3m

-SEK 76m

Sep 30 2020n/an/a

-SEK 146m

Jun 30 2020n/an/a

-SEK 150m

Mar 31 2020n/an/a

-SEK 144m

Dec 31 2019SEK 4mSEK 2m

-SEK 139m

Sep 30 2019n/an/a

-SEK 130m

Jun 30 2019n/an/a

-SEK 116m

Mar 31 2019n/an/a

-SEK 126m

Dec 31 2018SEK 3mSEK 800k

-SEK 123m

Compensation vs Market: Martin's total compensation ($USD464.53K) is about average for companies of similar size in the Swedish market ($USD441.65K).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.

CEO

Martin Welschof (63 yo)

6.3yrs

Tenure

SEK 5,167,000

Compensation

Dr. Martin Welschof, Ph D had been the Chief Executive Officer of Opsona Therapeutics Limited since February 2012. Dr. Welschof has been Chief Executive Officer at BioInvent Intl AB (publ) since 2018.He i...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Welschof
President & CEO6.3yrsSEK 5.17m0.034%
SEK 929.6k
Stefan Ericsson
Chief Financial Officer9yrsno data0.012%
SEK 332.1k
Marie Moores
Chief Operating Officer2.9yrsno datano data
Kristoffer Hansson
Senior Vice President of Technical Operations8.3yrsno data0.034%
SEK 925.5k
Björn Frendéus
Chief Scientific Officerno dataSEK 2.35m0.035%
SEK 958.3k
Cecilia Hofvander
Senior Director of Investor Relations3.9yrsno datano data
Andres McAllister
Chief Medical Officer8yrsno data0.0046%
SEK 124.8k
Ingrid Teige
Head of Preclinical Researchno datano datano data
Sylvie Ryckebusch
Chief Business Officer2.6yrsno data0.035%
SEK 949.0k
Ingunn Lindvig
Senior Vice President of Regulatory Affairs1.6yrsno datano data
Ashley Robinson
Senior VP of Strategy & Financeless than a yearno datano data

3.9yrs

Average Tenure

59yo

Average Age

Experienced Management: BINV's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bernd Seizinger
Independent Director7yrsSEK 595.00k0.10%
SEK 2.7m
Leonard Kruimer
Independent Chairman of the Board7yrsSEK 782.00k0.051%
SEK 1.4m
Thomas Hecht
Independent Director4.5yrsSEK 510.00kno data
Vincent Ossipow
Independent Director3.8yrsSEK 475.00kno data
Alexander Rudensky
Member of Scientific Advisory Board8yrsno datano data
Alexander Maximiliaan Eggermont
Member of Scientific Advisory Board3.3yrsno datano data
Falk Nimmerjahn
Member of Scientific Advisory Board8yrsno datano data
Kristoffer Bissessar
Independent Director4.7yrsSEK 520.00k0.044%
SEK 1.2m
Rienk Offringa
Member of Scientific Advisory Board8yrsno datano data
Mark Cragg
Member of Scientific Advisory Boardno datano datano data
Stephen Beers
Member of Scientific Advisory Boardno datano datano data
Martin Palsson
Employee Representative Director2.9yrsno datano data

5.8yrs

Average Tenure

61yo

Average Age

Experienced Board: BINV's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 03:53
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Camilla OxhamreCarnegie Investment Bank AB
Mattias HäggblomDanske Bank